Discover
CTMX
CytomX Therapeutics, Inc.
3.60
2 x 2.70
2 x 4.60
bid
ask
-
0.15
4.00%
2 @ 04:00 PM
3.58 -0.02 (0.61%)
| Ytd | -15.49% | |
| 1y | 52.54% |
3.58
day range
3.82
1.72
52 week range
8.21
| Open | 3.76 | Prev Close | 3.75 | Low | 3.58 | High | 3.82 | Mkt Cap | 783.73M |
| Vol | 5.57M | Avg Vol | 4.45M | EPS | -0.52 | P/E | N/A | Forward P/E | -9.74 |
| Beta | 2.48 | Short Ratio | 1.78 | Inst. Own | 75.69% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 3.63 | 200-d Avg | 4.11 | 1yr Est | 13.67 |
| Income Statement | |||
| Total Revenue | 10.26M | ||
| Revenues (USD) | 10.26M | ||
| Gross Profit | 10.26M | ||
| Operating Expenses | 29.93M | ||
| Research and Development Expense | 19.24M | ||
| Selling, General and Administrative Expense | 10.69M | ||
| Operating Income | -19.67M | ||
| Income Tax Expense | 59.00K | ||
| Net Income | -18.25M | ||
| Net Income Common Stock | -18.25M | ||
| Net Income Common Stock (USD) | -18.25M | ||
| Consolidated Income | -18.25M | ||
| Earnings per Basic Share | -0.10 | ||
| Earnings per Basic Share (USD) | -0.10 | ||
| Earnings per Diluted Share | -0.10 | ||
| Earning Before Interest & Taxes (EBIT) | -18.19M | ||
| Earning Before Interest & Taxes (USD) | -18.19M | ||
| Weighted Average Shares | 177.27M | ||
| Weighted Average Shares Diluted | 177.27M | ||
| Balance Sheet | |||
| Cash and Equivalents | 30.36M | ||
| Cash and Equivalents (USD) | 30.36M | ||
| Investments | 317.88M | ||
| Investments Current | 317.88M | ||
| Trade and Non-Trade Receivables | 646.00K | ||
| Current Assets | 353.10M | ||
| Property, Plant & Equipment Net | 3.35M | ||
| Total Assets | 359.36M | ||
| Debt Current | 2.86M | ||
| Total Debt | 2.86M | ||
| Current Liabilities | 34.02M | ||
| Total Liabilities | 39.41M | ||
| Accumulated Retained Earnings (Deficit) | -730.20M | ||
| Accumulated Other Comprehensive Income | 102.00K | ||
| Shareholders Equity | 319.94M | ||
| Shareholders Equity (USD) | 319.94M | ||
| Assets Non-Current | 6.26M | ||
| Total Debt (USD) | 2.86M | ||
| Deferred Revenue | 18.86M | ||
| Goodwill and Intangible Assets | 1.35M | ||
| Liabilities Non-Current | 5.39M | ||
| Trade and Non-Trade Payables | 1.37M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.38M | ||
| Net Cash Flow from Financing | 234.49M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 16.16M | ||
| Issuance (Purchase) of Equity Shares | 234.49M | ||
| Net Cash Flow from Investing | -192.78M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -192.78M | ||
| Net Cash Flow from Operations | -25.55M | ||
| Share Based Compensation | 4.71M | ||